Please login to the form below

Not currently logged in
PMLiVE Top Pharma List


The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Avonex was produced by Biogen Idec.

Biogen reveals strategic updates

Specifically, the company expects its growth to be driven by the continued strong sales of multiple sclerosis (MS) treatment, Avonex (Interferon beta-1a).

Elan hit by 'disaster' withdrawal

Both patients were involved in a trial that examined the effectiveness of Tysabri in combination with Biogen's existing MS drug, Avonex, on the market for nearly nine years.

Analysts back Tysabri return despite FDA concern

Tysabri was withdrawn a year ago after two patients taking it in combination with another Biogen MS drug, Avonex, developed a rare and often fatal brain infection known as progressive multifocal

Lectus wins USD 6.1m investment from Wellcome Trust

It is the fifth largest segment of the CNS market. The MS market is currently dominated by six treatments: Avonex (Biogen), Betaseron/Betaferon (Schering), Copaxone (Teva), Novatrone (Schering), Rebif (Serono/ Pfizer)

New accounts: May

Grandma Vines. Dermatology (consumer). hsdcommunications. Biogen Idec. Avonex. CNS. TVF Communications.

[ Previous 5 results ] 4 5 6 7 8 9 10 11 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs


Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...